Whole-Breast Versus Accelerated Partial Radiotherapy: 10-Year Results

Breast cancer surgeryfollowed by adjuvant, recurrence-reducing, partial breast irradiation (accelerated partial-breast irradiation, APBI) produced 10-year recurrence rates equal to whole-breast irradiation (WBI), according to Meattini and colleagues' follow-up study at the 2019 San Antonio Breast Cancer Symposium(Abstract GS4-06). Easier to deliver and tolerate, partial therapy may be acceptable in early breast cancer. Many patients undergo lumpectomy followed by radiotherapy . Lead author Dr. Icro Meattini of the University of Florence said: “Postoperative radiation remains the foundation of adjuvant breast treatment, significantly reducing regional cancer incidence.” Researchers have investigated whether partial irradiation prevents recurrence as effectively as whole-breast treatment.
Study Details
Meattini examined a randomized phase III clinical trial called the APBI IMRT studywith 10-year follow-up. Its 5-year results showed no recurrence or survival differences. It enrolled women older than 40, totaling 520 with stage I or II cancer. Between 2005-2013, randomization was 1:1 to APBI or WBI. APBI delivered in 5 daily fractions a total 30 Gy to the bed; WBI delivered over 25 days total 50 Gy, plus a 5-day 10 Gy bed boost. Arms were comparable in age, size, type, and endocrine therapy, with average 10-year follow-up. Most had hormone receptor-positive, HER2 -negative cancer and were over 50.
Key Findings
• At 10 years, recurrence was % 3.3 with APBI versus % 2.6 with WBI.
• At 10 years, overall survival was % 92.7 with APBI versus % 93.3 with WBI. Neither difference was significant. These reinforce promising 5-year findings and excellent control. Selected patients have similar outcomes regardless of partial or whole irradiation. Partial treatment causes fewer cosmetic changes but is more costly. It may reduce adverse effects, improve quality of life, and substantially shorten treatment. It exemplifies de-escalation in breast oncology and may be a relatively cost-effective, safe, effective optimal choice for many patients.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.